Endogenous Agmatine in Glutamatergic Pain Processing
谷氨酸疼痛处理中的内源胍丁胺
基本信息
- 批准号:6888156
- 负责人:
- 金额:$ 14.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-07-01 至 2006-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Provided by Applicant)
This application is for a Mentored Research Scientist Development Award (K01).
Recently, agmatine (decarboxylated arginine) has been isolated from mammalian
brain and spinal cord. Agmatine both antagonizes the NMDA receptor and inhibits
nitric oxide synthase (NOS). Because glutamate is thought to drive synaptic
plasticity by activating both NMDA receptors and NOS in series, it is
conceivable that agmatine participates in control of synaptic plasticity and
related behavioral phenomena (e.g. learning and memory, opioid tolerance,
chronic pain) as a neuromodulator of glutamate. Exogenously administered
agmatine has been shown to be neuroprotective in a model of cerebral ischemia
and to prevent development of opioid-induced tolerance, both thought to be
processes requiring plasticity. Preliminary data presented here demonstrates that
exogenous agmatine reverses nerve injury- and inflammation-induced allodynia and
hyperalgesia. The primary goal of the proposed study is whether endogenous
agmatine participates in the control of spinally derived pain. The proposed
studies will address that goal through pursuit of the following specific aims.
1). Determine the effect of endogenous agmatine in the spinal cord on nerve
injury- and inflammation-induced hyperalgesia. The induction of behaviorally
assessed allodynia and hyperalgesia will be compared across strains and
conditions with differing agmatine concentration in spinal cord extracts. 2).
Determine whether endogenous agmatine can be released from the spinal cord.
Agmatine concentration in spinal cord dialysate will be compared prior to and
following exposure to K+ and other depolarizing substances. 3). Determine how
localization of agmatine in spinal cord and dorsal root ganglia (DRG) is
related to that of other neurochemical markers. Antisera directed against
agmatine will be used in laser confocal and electron microscopy studies to
determine its regional, cellular, and ultrastructural localization in the
spinal cord and DRG as well as its relationship to the localization of
pain-related signaling molecules and proteins. 4.) Determine the relationship
between agmatine and glutamate-mediated excitation in the spinal cord.
Electrophysiological experiments will explore whether previously observed NMDA
receptor channel blockade or other action accounts for agmatine's block of
neuronal excitation and behavioral plasticity in spinal cord.
The results of these studies will clarify the role of endogenous agmatine in
nociception, its localization in relation to neurochemical markers of
nociception, and its relationship to the excitatory nociceptive transmitter
glutamate. The studies will also explore its participation as a novel
neuromodulator of central sensitization. Elucidation of the role of the
endogenous agmatine during hyperalgesia and allodynia may lead to the
development of a novel class of analgesic drugs or the identification of
therapeutic targets.
描述:(申请人提供)
本申请表是关于导师研究科学家发展奖(K01)的申请。
近年来,从哺乳动物中分离到了胍丁胺(脱羧精氨酸)。
大脑和脊髓。胍丁胺既能拮抗NMDA受体,又能抑制
一氧化氮合酶(NOS)。因为谷氨酸被认为可以驱动突触
通过一系列激活NMDA受体和NOS的可塑性,它是
可想而知,胍丁胺参与控制突触可塑性和
相关的行为现象(如学习和记忆、阿片类药物耐受性、
慢性疼痛)作为谷氨酸的神经调节剂。外源性给药
胍丁胺在脑缺血模型中被证明具有神经保护作用
以及防止阿片类药物诱导的耐受的发展,这两种方法都被认为是
需要可塑性的过程。这里提供的初步数据表明,
外源性胍丁胺逆转神经损伤和炎症诱导的痛觉过敏
痛觉过敏。拟议研究的主要目标是内生性
胍丁胺参与脊髓源性疼痛的控制。建议数
研究将通过追求以下具体目标来解决这一目标。
1)。测定脊髓内源性胍丁胺对神经的影响
损伤和炎症导致的痛觉过敏。行为的诱导性
评估的痛觉异常和痛觉过敏将在不同的菌株和
脊髓提取液中不同浓度胍丁胺的条件。2)。
确定内源性胍丁胺是否可以从脊髓中释放。
脊髓透析液中的胍丁胺浓度将在
在暴露于K+和其他去极化物质之后。3)。确定如何
胍丁胺在脊髓和背根神经节的定位
与其他神经化学标记物相关。抗血清
胍丁胺将用于激光共聚焦和电子显微镜研究
确定其在脑内的区域、细胞和超微结构定位
脊髓和背根神经节及其与脊髓损伤定位的关系
疼痛相关的信号分子和蛋白质。4.)确定关系
在胍丁胺和谷氨酸介导的脊髓兴奋之间。
电生理实验将探索之前观察到的NMDA
受体通道阻断或其他作用是胍丁胺阻断
脊髓神经元兴奋与行为可塑性。
这些研究的结果将阐明内源性胍丁胺在
伤害性感觉及其定位与神经化学标志物的关系
伤害性感觉及其与兴奋性伤害性递质的关系
谷氨酸。这些研究还将探索它作为一部小说的参与
中枢敏感化的神经调节剂。-阐明
痛觉过敏和痛觉异常时内源性胍丁胺可能导致
一类新型止痛药的开发或鉴定
治疗靶点。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse.
小鼠脊髓给药后胍丁胺的药效学和药代动力学研究。
- DOI:10.1124/jpet.105.086173
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Roberts,JohnC;Grocholski,BrentM;Kitto,KelleyF;Fairbanks,CarolynA
- 通讯作者:Fairbanks,CarolynA
Responsiveness of the Madison 109 lung carcinoma to maleic vinyl ether copolymer.
Madison 109 肺癌对马来酸乙烯基醚共聚物的反应性。
- DOI:10.3109/08923978309026441
- 发表时间:1983
- 期刊:
- 影响因子:0
- 作者:Klykken,PC;Loveless,SE;Morahan,PS;Munson,AE
- 通讯作者:Munson,AE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carolyn A Fairbanks其他文献
<strong>Relative effectiveness of different routes of AAV administration for gene therapy of mucopolysaccharidosis</strong>
- DOI:
10.1016/j.ymgme.2016.11.230 - 发表时间:
2017-01-01 - 期刊:
- 影响因子:
- 作者:
R. Scott McIvor;Karen Kozarsky;Kanut Laoharawee;Kelly M. Podetz-Pedersen;Kelley Kitto;Maureen Riedl;Chester B. Whitley;Lucy Vulchanova;Carolyn A Fairbanks;William H. Frey;Walter C. Low;Lalitha R. Belur - 通讯作者:
Lalitha R. Belur
Carolyn A Fairbanks的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carolyn A Fairbanks', 18)}}的其他基金
CAM: Roles in Chronic Pain Management and Research
CAM:在慢性疼痛管理和研究中的作用
- 批准号:
8529046 - 财政年份:2013
- 资助金额:
$ 14.19万 - 项目类别:
Agmatinergic Control of Opioid Tolerance and Drug Abuse
阿片类药物耐受性和药物滥用的阿片能控制
- 批准号:
6649166 - 财政年份:2002
- 资助金额:
$ 14.19万 - 项目类别:
相似海外基金
Impact of metabotropic glutamate receptor heteromerization on signaling and pharmacology
代谢型谷氨酸受体异聚化对信号传导和药理学的影响
- 批准号:
10637938 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
Subtype-Selective Metabotropic Glutamate Receptor PET Ligands
亚型选择性代谢型谷氨酸受体 PET 配体
- 批准号:
10576674 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
Structural and metabotropic signaling mechanisms of the delta2 glutamate receptor
δ2 谷氨酸受体的结构和代谢信号传导机制
- 批准号:
23K05967 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular basis of glutamate receptor trafficking in neuronal plasticity
神经元可塑性中谷氨酸受体运输的分子基础
- 批准号:
FT220100485 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
ARC Future Fellowships
Metabotropic glutamate receptor signalling: a new drug target for longevity.
代谢型谷氨酸受体信号传导:长寿的新药物靶点。
- 批准号:
BB/T001488/2 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
Research Grant
Analysis of modulation of the metabotropic glutamate receptor type 5 in a novel heritable model of drug abuse vulnerability
药物滥用易感性新型遗传模型中 5 型代谢型谷氨酸受体的调节分析
- 批准号:
10754809 - 财政年份:2023
- 资助金额:
$ 14.19万 - 项目类别:
Regulation of activity-induced glutamate receptor trafficking in neurons
神经元中活动诱导的谷氨酸受体运输的调节
- 批准号:
DP220101645 - 财政年份:2022
- 资助金额:
$ 14.19万 - 项目类别:
Discovery Projects
Structure and Function of native kainate-type ionotropic glutamate receptor complexes
天然红藻氨酸型离子型谷氨酸受体复合物的结构和功能
- 批准号:
10696091 - 财政年份:2022
- 资助金额:
$ 14.19万 - 项目类别:
PET imaging of ionotropic glutamate receptor signaling in Alzheimer's disease
阿尔茨海默病中离子型谷氨酸受体信号传导的 PET 成像
- 批准号:
10574694 - 财政年份:2022
- 资助金额:
$ 14.19万 - 项目类别: